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Introduction
The effectiveness of breast cancer screening programmes
in reducing mortality from breast cancer is dependent on
maintaining adequate attendance at screening among eli-
gible women. Information regarding the general character-
istics and health of women who do and do not attend for
breast cancer screening is limited and representative data
are difficult to obtain. This paper compares the character-
istics of women who do and do not attend for breast
cancer screening through the National Health Service
Breast Screening Programme (NHSBSP), in terms of age,
deprivation and prescriptions for a variety of commonly
used medications. It also assesses the characteristics of
women from the same population who agreed to partici-
pate in the Million Women Study, which recruits women
through the NHSBSP.
HRT = hormone replacement therapy; NHSBSP = National Health Service Breast Screening Programme.
Available online http://breast-cancer-research.com/content/4/1/R1
Abstract
Background: Information regarding the characteristics and health of women who do and do not attend
for breast cancer screening is limited and representative data are difficult to obtain.
Methods: Information on age, deprivation and prescriptions for various medications was obtained for
all women at two UK general practices who were invited to breast cancer screening through the
National Health Service Breast Screening Programme. The characteristics of women who attended
and did not attend screening were compared.
Results: Of the 1064 women invited to screening from the two practices, 882 (83%) attended
screening. Screening attenders were of a similar age to non-attenders but came from significantly less
deprived areas (30% of attenders versus 50% of non-attenders came from the most deprived areas,
P < 0.0001) and were more likely to have a current prescription for hormone replacement therapy
(32% versus 19%, P < 0.0001). No significant differences in recent prescriptions of medication for
hypertension, heart disease, hypercholesterolaemia, diabetes mellitus, asthma, thyroid disease or
depression/anxiety were observed between attenders and non-attenders.
Conclusion: Women who attend the National Health Service Breast Screening Programme come from
less deprived areas and are more likely to have a current prescription for hormone replacement therapy
than non-attenders, but do not differ in terms of age or recent prescriptions for various other medications.
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Materials and methods
This study was based at the Deer Park Medical Centre in
Witney, Oxfordshire (UK) and the Kingswood Surgery in
Swindon, Wiltshire (UK). These practices were chosen to
cover a relatively broad social class spectrum, from the
comparatively affluent, semi-rural practice in Witney to the
less affluent inner-city practice in Swindon. A comput-
erised record of prescriptions has been kept at the Witney
practice since 1992 and at the Swindon practice since
1994. All women invited to attend the NHSBSP from
these general practices during 1998 were matched to the
practices’ computerised prescription records. All medica-
tions prescribed in the six months before screening were
noted. Additional details were gathered on prescriptions
for hormone replacement therapy (HRT), including date of
first and most recent prescription of HRT.
The Million Women Study is a population-based multicen-
tre prospective study in the UK aiming to investigate the
effects of HRT on health. The methods are described in
detail elsewhere [1]. Women invited to screening at par-
ticipating NHS breast screening centres receive a ques-
tionnaire for the Million Women Study accompanying their
invitation and are asked to join the study by returning the
recruitment form when they attend for screening. Women
participating in the Million Women Study from the Witney
and Swindon practices were identified by matching the list
of study participants against the list of women invited to
breast cancer screening. Prescription data from women
not participating in the Million Women Study were
extracted anonymously under the supervision of practice
staff. Ethical approval for the study was given by the
Central Oxfordshire Research Ethics Committee and the
Swindon Research Ethics Committee.
Ascertainment and classification of variables
Attendance at screening was defined as having under-
gone mammographic screening for breast cancer at the
respective screening centre within the six month period
following the screening invitation. The Townsend score,
based on each participant’s postcode, was used as a
measure of deprivation; this score is obtained using infor-
mation regarding unemployment, overcrowding and car
and home ownership within each relevant enumeration
district [2]. In the general population, this score usually
ranges from –3 to +3, and a higher score represents
worse deprivation.
Ever use of HRT was considered to be the presence of
more than one prescription for oral or transdermal HRT in
the prescription record. Women who had received one
isolated prescription (which had not necessarily been dis-
pensed or taken) were therefore considered non-users. A
woman was considered to be a current user of HRT if her
last prescription date was within six months before her
screen date, since a single prescription can provide med-
ication for this period of time. Other medications on the
prescription record were classified by a medically qualified
researcher (Emily Banks) according to the following broad
treatment categories: anti-hypertensive medications (e.g.
relevant beta-blockers, diuretics, angiotensin converting
enzyme inhibitors, calcium channel blockers and others);
heart disease medications (e.g. digoxin, glyceryl trinitrate,
etc); lipid lowering medications (e.g. statins, clofibrate,
etc.); anti-diabetic medications (e.g. insulin, oral hypogly-
caemics); asthma medications (e.g. bronchodilators,
inhaled steroids, etc.); thyroid medications (e.g. thyroxine,
carbimazole, etc.); and medications for depression/anxiety
(e.g. anti-depressants, anxiolytics). Medications not corre-
sponding to these categories were not coded. Medica-
tions that were not specific to one class of disorders were
coded only in one treatment category, hierarchically as
written above. Current treatment was considered to be a
prescription within six months prior to the screening date.
Analysis
Women who had left the practice, either according to the
breast screening centre records or the practice records,
were excluded from the analyses (Table 1). Women who
contacted the breast screening centre and indicated that
they had recently been screened elsewhere or who were
deemed ineligible on medical grounds were also excluded,
as were those who deferred attendance at screening.
The Student’s t-test was used for comparisons of mean
age and deprivation between screening attenders and non-
attenders. The same comparisons were also made among
women who attended screening, comparing those who
participated in the Million Women Study with those who
did not. For comparison of prescription record medication
use between groups, simple chi-squared tests were used.
Results
Of the 1064 eligible women who were invited to screen-
ing, 882 (83%) attended screening. Among those who
attended, 570 (65%) filled in the Million Women Study
Table 1
Study population
Attendance status n %
Total invited to screening 1133 100
Exclusions
Recently screened 23 2
Deferred attendance 18 2
Ineligible on medical grounds 17 2
Moved away 11 1
Total eligible 1064 94Page 3 of 6
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questionnaire and gave signed permission for follow-up
(Table 2).
Age and deprivation
The average age and age distribution of the attenders and
non-attenders was similar (Table 2). Women who did not
attend screening, however, came from more deprived
areas than women who attended screening (50% of non-
attenders versus 30% of attenders came from the most
deprived areas, P < 0.0001). Among women who
attended screening, there was no significant difference
between Million Women Study participants and non-par-
ticipants in terms of age or level of deprivation (Table 2).
Prescriptions for HRT
Overall, 42% of women who attended screening had more
than one prescription for HRT recorded at some time
since the records started and 32% had prescription
records consistent with current use of HRT, compared to
27% and 19% , respectively, among women who did not
attend screening (χ2
1 = 13.5, P < 0.0001 and χ2
1 = 13.6,
P < 0.0001, respectively; Fig. 1).
Restricting the analysis to women who attended screen-
ing, statistical comparisons were possible between Million
Women Study participants and non-participants. 35% of
Million Women Study participants had prescription
records compatible with current use of HRT, compared to
28% among women who attended screening but did not
join the study (χ2
1 = 5.2,  P = 0.02). Ever use of HRT
during the time covered by the prescription record was
significantly more common among women participating in
the Million Women Study, compared to women who
attended screening but did not join the Million Women
Study (45% versus 35%, χ2
1 = 7.7, P = 0.005).
The prevalence of prescriptions compatible with current
use of HRT was 30% in the general practice population
eligible for screening, 32% among women who attended
screening and 35% among women who attended screen-
ing and participated in the Million Women Study (Fig. 1).
Current use of various other medications
There was no significant difference between attenders
and non-attenders with respect to the proportion that had
recently been prescribed medications for hypertension
(χ2
1 = 0.6, P = 0.4), heart disease (χ2
1 = 3.4, P = 0.07),
cholesterol lowering (χ2
1 = 0.4, P = 0.5), diabetes melli-
tus (χ2
1 = 1.9,  P = 0.2), asthma (χ2
1 = 3.5,  P = 0.06),
thyroid disease (χ2
1 = 1.3, P = 0.2) or depression/anxiety
Available online http://breast-cancer-research.com/content/4/1/R1
Table 2
Age, deprivation, screening attendance and participation in the Million Women Study
t-test – P value
Did not attend Among
Attended screening screening Overall screened
Million Women Study MWS
Screened participant
All eligible women  Total  Participant Non-participant  Total  vs not vs
n (%) n (%) n (%) n (%) n (%) screened non-participant
Age
49–54 353 (33) 284 (32) 195 (34) 89 (29) 69 (38)
55–59 286 (27) 239 (27) 147 (26) 92 (29) 47 (26)
60+ 425 (44) 359 (41) 228 (40) 131 (42) 66 (46)
Mean age (95% CI) 57.4  57.5  57.4  57.7  57.1  0.4 0.3
(57.1–57.7) (57.2–57.8) (57.0–57.8) (57.2–58.2) (56.4–57.8)
Deprivation level*
Least deprived 348 (33) 303 (35) 204 (36) 99 (32) 45 (25)
Medium deprived 348 (33) 304 (35) 186 (33) 118 (38) 44 (25)
Most deprived 351 (34) 263 (30) 170 (31) 93 (30) 88 (50)
Mean deprivation (95% CI) 0.42  0.22  0.20  0.26  1.41  < 0.0001 0.8
(0.21–0.63) (–0.06–0.44) (–0.09–0.48) (–0.11–0.62) (0.89–1.92)
Total† 1064 (100) 882 (83) 570 (54) 312 (29) 182 (17)
CI, confidence interval. *Measured by Townsend score. A higher score corresponds to more deprivation. †Numbers do not always add up to total
due to missing values.Page 4 of 6
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(χ2
1 = 0.002, P = 0.9). In total, 44% of women who did
not attend screening had prescriptions for at least one of
these conditions, compared with 41% of women who
attended screening (χ2
1 = 0.5, P = 0.5; Fig. 1).
There were no significant differences between Million
Women Study participants and non-participants who
attended screening with respect to the proportion that had
recently been prescribed medications for hypertension
(χ2
1 = 2.3, P = 0.1), heart disease (χ2
1 = 0.004, P = 0.9),
cholesterol lowering (χ2
1 = 3.0, P = 0.1), diabetes mellitus
(χ2
1 = 0.01, P = 0.9), asthma (χ2
1 = 0.4, P = 0.5), thyroid
disease (χ2
1 = 1.2, P = 0.3), depression/anxiety (χ2
1 = 1.6,
P = 0.2) or with respect to the proportion of women pre-
scribed some type of medication for at least one of these
conditions (χ2
1 = 0.2, P = 0.7; Fig. 1). There were no large
differences between Million Women Study participants and
the general population in terms of current prescriptions for
these medications, nor were there any large differences
between Million Women Study participants and the overall
group of women who attended screening.
Discussion
These data indicate that women who attend for breast
cancer screening are significantly more likely to come from
less deprived areas than women who do not attend for
screening, and are significantly more likely to have a pre-
scription record compatible with current use of HRT. No
significant differences between attenders and non-atten-
ders were observed in terms of age or prescriptions for
various other medications. Women who went on to partici-
pate in the Million Women Study were slightly more likely
to be prescribed HRT but did not differ from non-partici-
pants in terms of age, deprivation level or use of other pre-
scription medications.
The data presented here are consistent with previous
reports in finding lower socio-economic status among
women who do not attend for breast cancer screening
compared to women who do attend [3–7]. Our study finds
that 25% of women from the most deprived areas
included in the study (88 of 351) did not attend screening,
compared to 13% non-attendance among women from
the medium deprived (44 of 348) and least deprived (45
of 348) areas. This problem is well recognised and
attempts to improve uptake in deprived areas continue to
be a priority for the NHSBSP.
Previous studies suggest that women who attend breast
screening are less likely than non-attenders to have
serious illness, but are more likely to have visited a physi-
cian recently and to have made use of other screening ser-
vices [3,6–9]. One study found perceived health status to
be similar in attenders and non-attenders [10] while
another found that non-attenders had poorer perceived
health status than attenders [8]. We did not observe sig-
nificant differences between attenders and non-attenders
in terms of recent prescriptions for common illnesses.
Such prescriptions have been shown to agree well with
self-reported treatment for various illnesses [11].
Breast Cancer Research    Vol 4 No 1 Banks et al.
Figure 1
Prevalence of prescriptions for HRT and other medications according to screening attendance and participation in the Million Women Study.
Horizontal bars indicate 95% confidence intervals. *A prescription for HRT within the past six months is considered current use of HRT; a
prescription for HRT on the prescription record but no prescription within the past six months is considered past use of HRT. †Any prescription
within the past six months for medications for conditions listed here.
0% 10% 20% 30% 40% 50% 60%
any of the above
depression/anxiety
thyroid disease
asthma
diabetes mellitus
cholesterol lowering
heart disease
hypertension
past
current
Proportion with a prescription recorded for specified medication
all eligible women
did not attend breast screening
attended breast screening
Million Women Study participants
Medication for
†
HRT use*Prescriptions for HRT were significantly more common
among women who attended screening than among those
who did not attend. Around 70% of women who attend for
screening at participating NHS breast screening centres
take part in the Million Women Study [1]. The prevalence
of current use of HRT was 30% in the eligible general
practice population invited to screening, 32% among
women attending screening and 35% in Million Women
Study participants. These findings are consistent with
those of previous studies that have shown that women
who take HRT are more likely to make use of various
medical and screening services, including mammography,
than women who do not use HRT [8,12,13]. Furthermore,
the increasing awareness that women who use HRT are at
a higher risk of breast cancer than non-users [14] may
also encourage them to attend screening. Differences in
the prevalence of use of HRT were greater between those
who did and did not attend screening than between those
who attended screening and did or did not participate in
the Million Women Study.
Previous studies comparing attenders and non-attenders
at screening have been based on interviews and postal
questionnaires and have been hampered by the fact that
women who do not attend breast cancer screening have a
low response rate to surveys [3–6,9,15,16]. Many studies
report response rates of 50% or less in non-attenders
[6,9,10,16]. Other problems have arisen where the non-
attenders have been a heterogeneous group composed of
women who have been recently screened elsewhere and
women who do not attend mammographic screening at all
[9]. In our study, deprivation, screening and prescription
record data were equally available for all women, and were
independent of their subsequent attendance at screening.
Women known to have declined screening because of
being screened recently elsewhere were excluded.
The limitations of the data presented here should also be
acknowledged. The study was conducted at two general
practices in Southern England and the practices were
selected to reflect different levels of deprivation in their
respective populations. Women invited to screening from
the inner-city Swindon practice were significantly more
deprived than those invited from the semi-rural Witney
practice (mean deprivation score 1.27 versus –1.83,
P < 0.0001). However, results may not be generalisable to
the entire UK. For some variables there was limited power
to ascertain differences between the groups, particularly
in terms of prescriptions for uncommon conditions such
as heart disease or diabetes. In addition, some of the
women who did not attend for screening may have left the
practice and would, therefore, not have had recent pre-
scriptions for various medications, resulting in the preva-
lence of prescriptions appearing lower than is really the
case in non-participants. Eleven women (1%) were
excluded from the study because they were known to have
left the practice since invitations to breast screening had
been sent out, but whether or not more had left the prac-
tice is not known.
Conclusion
In summary, women who attended screening came from
less deprived areas and were more likely to use HRT than
women who did not attend screening. Women who went
on to take part in the Million Women Study did not differ
substantially from the overall population of women who
attended screening.
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